Welcome to My Column, ‘The Mighty Mind’

Welcome to My Column, ‘The Mighty Mind’

Welcome to “The Mighty Mind.” When I was diagnosed with ALS at age 28 in 2015, I felt like I had lost everything. My body, without warning or reason, had turned on me, and that meant the end of so much. My teaching career, and dreams of motherhood and growing…

National Institutes of Health Awards $30 Million to Support Development of 3-D Models of Disease

The National Institutes of Health has awarded $30 million over two years to 13 researchers who are developing three-dimensional models of amyotrophic lateral sclerosis and other diseases. Researchers say the initiative is aimed at tackling a translational science problem: More than 60 percent of therapies prove ineffective in clinical trials of…

Filmmaker Finishes Film Project With Advanced ALS

In this video from CBS Sunday Morning, follow the journey of award-winning filmmaker Simon Fitzmaurice as he completes his pet project, a film called My Name is Emily, despite being diagnosed with amyotrophic lateral sclerosis (ALS) eight years ago. MORE: Explaining the progression…

6 Tips to Reduce Stress and Help You Relax

Everyone suffers from stress from time to time but when you have a chronic disease, stress not only adds to your everyday burden but can often exacerbate the symptoms of your condition. While we can’t avoid stress altogether, there are ways that we help ourselves relax more and not let things…

Human Skin Cells Successfully Converted into Motor Neurons

Scientists have discovered how adult skin cells can be converted into motor neurons without transitioning them through a stem cell state. The findings promise to help researchers better understand motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). The study, “MicroRNAs Induce a Permissive Chromatin Environment that…

Amylyx, Project ALS Collaborate on Preclinical Study to Test AMX0035 as Potential ALS Therapy

Project ALS and Amylyx Pharmaceuticals will collaborate on preclinical studies of Amylyx’s lead compound AMX0035 as a potential treatment for patients with amyotrophic lateral sclerosis (ALS). These studies will complement Amylyx’s recently initiated Phase 2 CENTAUR clinical trial (NCT03127514), which will evaluate AMX0035 in 132 patients. Since mitochondrial…